- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 19.05. | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 15.05. | iSpecimen Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 3 | SEC Filings | ||
| 02.05. | iSpecimen Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 14.04. | iSpecimen Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | iSpecimen Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 11.03. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | iSpecimen Inc.: iSpecimen Secures Suppliers for COVID-style hMPV Outbreak | 450 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus... ► Artikel lesen | |
| 16.01. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.12.24 | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | iSpecimen expands cancer biospecimen services for research | 3 | Investing.com | ||
| 20.12.24 | iSpecimen Inc.: iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens | 377 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025... ► Artikel lesen | |
| 13.12.24 | iSpecimen Up on Positive Results From NDQ | 2 | Baystreet.ca | ||
| 13.12.24 | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | 943 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| 13.12.24 | iSpecimen Inc.: iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers | 319 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen appoints Robert Lim as CEO | 1 | Seeking Alpha | ||
| 12.12.24 | iSpecimen Inc.: iSpecimen Appoints Robert Lim as CEO and Director | 547 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 71,82 | -0,15 % | Does Illumina (ILMN) Have Good Long-Term Growth Prospects? | ||
| CRISPR THERAPEUTICS | 34,200 | +1,18 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 6,732 | +1,78 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| EDITAS MEDICINE | 1,542 | -1,75 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
| NEUROCRINE BIOSCIENCES | 110,75 | +1,61 % | Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 | Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 14,540 | +1,08 % | Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" | ||
| GALAPAGOS NV | 24,560 | -0,49 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,200 | +1,11 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 | - Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate - - The trial evaluated three doses... ► Artikel lesen | |
| TWIST BIOSCIENCE | 26,690 | +0,60 % | Cathie Wood setzt wieder auf Nvidia, auch TSMC wandert verstärkt ins Portfolio, mit Twist Bioscience wird eine Wette eingegangen und Palantir scheint der Investorin zu heiß geworden | Die Börse wird oft als seriöser und kühler Ort angesehen, doch sind die Handelsplätze längst nicht frei von Emotionen. Auch hier gibt es prominente Investorinnen und Investoren, die teils wie Popsternchen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,575 | 0,00 % | Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? | ||
| REPLIGEN | 110,90 | +0,09 % | Repligen auf der William Blair Konferenz: Innovation treibt Wachstum | ||
| ROCKET PHARMACEUTICALS | 2,415 | -0,45 % | Evercore ISI cuts Rocket Pharmaceuticals stock rating to in line | ||
| XBIOTECH | 2,540 | +1,60 % | XFRA 4XB: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PERSONALIS | 4,526 | +2,12 % | Personalis enthüllt: ctDNA-Test sagt Rückfall bei Gebärmutterhalskrebs voraus | ||
| SPERO THERAPEUTICS | 2,220 | -1,11 % | Why Spero Therapeutics, Inc. (SPRO) Surged Last Week |
ISPECIMEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.